Neurimmune welcomes NovaGo Therapeutics’ appointment of Ian Metcalfe as CEO

Neurimmune welcomes the news that NovaGo Therapeutics appointed Ian Metcalfe as Chief Executive Officer. NovaGo Therapeutics is a strategic partner of Neurimmune and a development stage biotech company focused on human antibody therapeutics targeting blood vessel growth, nerve growth, and regeneration. Ian Metcalfe joins at a pivotal time in NovaGo’s development, as the company prepares to move into clinical proof-of-concept studies in diabetic retinopathy.